TREATMENT OF HIV-INFECTED INDIVIDUALS

摘要

The invention concerns an immunogenic compound comprising an antigenic peptide derived from the HIV gp41 protein, for reducing a Peripheral Blood Mononuclear Cells (PBMC)-associated ΗIV DNA level in an HIV-infected individual under anti-retroviral treatment.